Alnylam Pharmaceuticals Q3 2024 Earnings Report

Alnylam Pharmaceuticals (NASDAQ: ALNY) has announced a significant growth in global net product revenue for Q3 2024, reaching $420 million, a 34% increase year-over-year. The TTR franchise, including products ONPATTRO and AMVUTTRA, contributed $309 million to this revenue, serving nearly 5,000 patients worldwide. The company also provided pipeline updates highlighting advancements in Alzheimer’s and Huntington’s disease treatments while reaffirming its 2024 revenue guidance.

Key Takeaways

• Alnylam reported a 34% increase in global net product revenue, totaling $420 million.
• The TTR franchise led with $309 million, benefiting nearly 5,000 patients globally.
• Significant progress reported from the HELIOS-B study on vutrisiran and developments in CNS disorders.
• Alnylam aims to double its clinical pipeline by the end of 2025.
• Revenue guidance for 2024 is $1.575 billion to $1.65 billion.

Company Outlook

• Preparing for the U.S. and EU launch of AMVUTTRA in 2025, with increased investments anticipated.
• Commitment to achieving corporate strategic goals and expanding clinical pipeline.
• Exploration of business development opportunities to bolster growth.

Highlights

Bearish:
– Collaboration revenues declined to $57 million due to the absence of prior upfront payments.

Bullish:
– Royalty revenues rose to $23 million, with a 80% gross margin on product sales.
– Strong demand for TTR products continues, reflecting competitive advantages.

Misses

• The ALN-KHK program for type 2 diabetes has been discontinued to allocate resources efficiently.

Q&A Highlights

• The company is exploring options for business development and future product indications.

In summary, Alnylam Pharmaceuticals displayed robust financial growth and exciting pipeline advancements in Q3 2024, positioning itself for ongoing innovation in biopharmaceuticals.

InvestingPro Insights

• Alnylam's impressive growth aligns with strong financial metrics, revealing a 107% increase in quarterly revenues as of Q2 2024, with a 87% gross profit margin.
• Despite growth, analysts predict no profitability in the upcoming year, emphasizing focus on long-term goals.

Full Transcript

Operator: Good day, everyone, and welcome to today's Alnylam Pharmaceuticals Q3 2024 Earnings Conference Call….

Christine Lindenboom: Good morning. I'm Christine Lindenboom, Chief Corporate Communications Officer at Alnylam. With me today are…

Yvonne Greenstreet: Thanks, Christine, and thank you, everyone, for joining the call today. The third quarter of 2024 marked a period of continued progress for Alnylam…

Tolga Tanguler: Thanks, Yvonne, and good morning, everyone. Q3 was another strong quarter for our commercial portfolio…

Pushkal Garg: Thanks, Tolga, and good morning, everyone. As you all know, Q3 was very exciting for our TTR franchise…

Jeff Poulton: Thanks, Pushkal, and good morning, everyone. I'm pleased to be presenting a summary of Alnylam's Q3 2024 financial results…

Christine Lindenboom: Thank you, Tolga…

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.